These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

147 related articles for article (PubMed ID: 4069813)

  • 1. Increased dosage requirements of tobramycin and gentamicin for treating Pseudomonas pneumonia in patients with cystic fibrosis.
    Mann HJ; Canafax DM; Cipolle RJ; Daniels CE; Zaske DE; Warwick WJ
    Pediatr Pulmonol; 1985; 1(5):238-43. PubMed ID: 4069813
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Gentamicin and tobramycin pharmacokinetics in patients with cystic fibrosis.
    Bauer LA; Piecoro JJ; Wilson HD; Blouin RA
    Clin Pharm; 1983; 2(3):262-4. PubMed ID: 6883955
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of 6 and 8 hourly tobramycin dosing intervals in treatment of pulmonary exacerbations in cystic fibrosis patients.
    Winnie GB; Cooper JA; Witson J; Cowan RG; Mayer D; Lepow M
    Pediatr Infect Dis J; 1991 May; 10(5):381-6. PubMed ID: 1906161
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Azlocillin in cystic fibrosis.
    Malmborg AS; Alfredsson H; Strandvik B
    Isr J Med Sci; 1983 Nov; 19(11):1001-3. PubMed ID: 6662681
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Disposition of tobramycin in patients with cystic fibrosis: a prospective controlled study.
    Levy J; Smith AL; Koup JR; Williams-Warren J; Ramsey B
    J Pediatr; 1984 Jul; 105(1):117-24. PubMed ID: 6376743
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacokinetics of tobramycin in patients with cystic fibrosis. Implications for the dosing interval.
    Horrevorts AM; Degener JE; Dzoljic-Danilovic G; Michel MF; Kerrebijn KF; Driessen O; Hermans J
    Chest; 1985 Aug; 88(2):260-4. PubMed ID: 4017681
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gentamicin and tobramycin compared in the treatment of mucoid pseudomonas lung infections in cystic fibrosis.
    Martin AJ; Smalley CA; George RH; Healing DE; Anderson CM
    Arch Dis Child; 1980 Aug; 55(8):604-7. PubMed ID: 7436516
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Individualization of tobramycin dosage in patients with cystic fibrosis.
    Hsu MC; Aguila HA; Schmidt VL; Munzenberger PJ; Kauffman RE; Polgar G
    Pediatr Infect Dis; 1984; 3(6):526-9. PubMed ID: 6440126
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of piperacillin vs. ticarcillin plus tobramycin in the treatment of acute pulmonary exacerbations of cystic fibrosis.
    Jackson MA; Kusmiesz H; Shelton S; Prestidge C; Kramer RI; Nelson JD
    Pediatr Infect Dis; 1986; 5(4):440-3. PubMed ID: 3725655
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Suggestions for the optimization of the initial tobramycin dose in adolescent and adult patients with cystic fibrosis.
    Touw DJ; Vinks AA; Heijerman HG; Hermans J; Bakker W
    Ther Drug Monit; 1994 Apr; 16(2):125-31. PubMed ID: 8009558
    [TBL] [Abstract][Full Text] [Related]  

  • 11. In vitro activity of aztreonam combined with tobramycin and gentamicin against clinical isolates of Pseudomonas aeruginosa and Pseudomonas cepacia from patients with cystic fibrosis.
    Bosso JA; Saxon BA; Matsen JM
    Antimicrob Agents Chemother; 1987 Sep; 31(9):1403-5. PubMed ID: 3118798
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Dosing implications of altered gentamicin disposition in patients with cystic fibrosis.
    Kearns GL; Hilman BC; Wilson JT
    J Pediatr; 1982 Feb; 100(2):312-8. PubMed ID: 7035640
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glomerular and Tubular Renal Function after Repeated Once-Daily Tobramycin Courses in Cystic Fibrosis Patients.
    Stehling F; Büscher R; Grosse-Onnebrink J; Hoyer PF; Mellies U
    Pulm Med; 2017; 2017():2602653. PubMed ID: 28133546
    [No Abstract]   [Full Text] [Related]  

  • 14. Comparison of gentamicin and tobramycin nephrotoxicity in patients receiving individualized-pharmacokinetic dosing regimens.
    Pancorbo S; Compty C; Heissler J
    Biopharm Drug Dispos; 1982; 3(1):83-8. PubMed ID: 7082782
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Tobramycin therapy of infections due to Pseudomonas aeruginosa in patients with cystic fibrosis: effect of dosage and concentration of antibiotic in sputum.
    McCrae WM; Raeburn JA; Hanson EJ
    J Infect Dis; 1976 Aug; 134 Suppl():S191-3. PubMed ID: 972281
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Direct determination of tobramycin clearance in patients with mild-to-moderate cystic fibrosis.
    Kildoo CW; Harralson AF; Folli HL; Kelly PC; Nussbaum E
    Drug Intell Clin Pharm; 1987; 21(7-8):639-42. PubMed ID: 3608813
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemotherapy of chronic infections with mucoid Pseudomonas aeruginosa in lower airways of patients with cystic fibrosis.
    Friis B
    Scand J Infect Dis; 1979; 11(3):211-7. PubMed ID: 118525
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Renal and auditory toxicity of high-dose, prolonged therapy with gentamicin and tobramycin in pseudomonas endocarditis.
    Tablan OC; Reyes MP; Rintelmann WF; Lerner AM
    J Infect Dis; 1984 Feb; 149(2):257-63. PubMed ID: 6421944
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Piperacillin and tobramycin in the treatment of Pseudomonas lung infections in cystic fibrosis.
    Hoogkamp-Korstanje JA; van der Laag J
    J Antimicrob Chemother; 1983 Aug; 12(2):175-83. PubMed ID: 6619055
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Comparison of the pharmacokinetics of tobramycin administered in a single daily dose or in 3 doses in cystic fibrosis].
    Canis F; Trivier D; Vic P; Ategbo S; Turck D; Husson MO
    Pathol Biol (Paris); 1998 Jun; 46(6):449-51. PubMed ID: 9769880
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.